Together we will beat cancer

Donate

NICE recommends pembrolizumab for 1,600 more people with breast cancer

The “potentially life-saving” immunotherapy drug pembrolizumab is now recommended for some people with early triple negative breast cancer in England and Wales.

Read More

New treatment for Waldenstrom’s macroglobulinaemia in England

The National Institute for Health and Care Excellence (NICE) has recommended zanubrutinib (Brukinsa) as an option for treating some people…

Read More

NICE doesn’t recommend olaparib for patients with certain prostate cancers

NICE does not recommend olaparib (Lynparza) for people with a type of advanced prostate cancer, as the treatment is not deemed cost-effective

Read More

New targeted treatment for early breast cancer could reduce risk of relapse

A targeted cancer drug has been approved to treat some people with breast cancer that has a high-risk of returning.

Read More

NICE doesn’t recommend ibrutinib drug for those with Waldenstrom’s macroglobulinaemia

Ibrutinib, a drug used to treat Waldenstrom’s macroglobulinaemia, is not being recommended by the National Institute for Health and Care Excellence in England

Read More

Triple negative breast cancer drug given initial ‘no’ for NHS in England

Sacituzumab govitecan (Trodelvy) is not being recommended by NICE for use in England as a treatment for some people with triple-negative breast cancer.

Read More

Immunotherapy treatment fast tracked to treat lung cancer patients in England

Hope for patients with early-stage lung cancer as new treatment approved for use on NHS England.

Read More

First targeted treatment approved for advanced prostate cancer on NHS in Scotland

The targeted drug olaparib has been approved for some people with a type of advanced prostate cancer on the NHS in Scotland.

Read More